Standout Papers

Cluster Analysis and Clinical Asthma Phenotypes 2002 2026 2010 2018 1.4k
  1. Cluster Analysis and Clinical Asthma Phenotypes (2008)
    Pranabashis Haldar, Ian Pavord et al. American Journal of Respiratory and Critical Care Medicine
  2. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma (2009)
    Pranabashis Haldar, Christopher E. Brightling et al. New England Journal of Medicine
  3. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial (2002)
    Ruth H. Green, Christopher E. Brightling et al. The Lancet
  4. Asthma (2017)
    Alberto Papi, Christopher E. Brightling et al. The Lancet
  5. Mast-Cell Infiltration of Airway Smooth Muscle in Asthma (2002)
    Christopher E. Brightling, Peter Bradding et al. New England Journal of Medicine
  6. Evidence of a Role of Tumor Necrosis Factor α in Refractory Asthma (2006)
    Mike Berry, Beverley Hargadon et al. New England Journal of Medicine
  7. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma (2021)
    Andrew Menzies‐Gow, Jonathan Corren et al. New England Journal of Medicine
  8. Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease (2012)
    Mona Bafadhel, Susan McKenna et al. American Journal of Respiratory and Critical Care Medicine
  9. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies (2016)
    Héctor Ortega, Steven W. Yancey et al. The Lancet Respiratory Medicine
  10. Lung microbiome dynamics in COPD exacerbations (2016)
    Zhang Wang, Mona Bafadhel et al. European Respiratory Journal
  11. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Sarah Diver, Latifa Khalfaoui et al. The Lancet Respiratory Medicine
  12. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial (2021)
    Steven G. Kelsen, Ioana Agache et al. Journal of Allergy and Clinical Immunology
  13. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update (2023)
    Mark L Levy, Leonard B. Bacharier et al. npj Primary Care Respiratory Medicine
  14. Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation (2023)
    Sally Singh, Molly M Baldwin et al. The Lancet Respiratory Medicine
  15. Airway hyperresponsiveness in asthma: The role of the epithelium (2024)
    Peter Bradding, Celeste Porsbjerg et al. Journal of Allergy and Clinical Immunology
  16. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma (2024)
    Richard Russell, Louis‐Philippe Boulet et al. European Respiratory Journal

Immediate Impact

4 by Nobel laureates 4 from Science/Nature 115 standout
Sub-graph 1 of 14

Citing Papers

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
2025 Standout
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
2024 Standout
6 intermediate papers

Works of Christopher E. Brightling being referenced

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
2021 Standout
Biomarkers that Predict and Guide Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease
2013
and 6 more

Author Peers

Author Last Decade Papers Cites
Christopher E. Brightling 20456 16720 6789 405 28.0k
Pascal Chanez 18206 14143 5069 408 24.8k
Ian Pavord 27308 23603 5857 501 33.7k
Sally E. Wenzel 26889 18317 9120 328 33.8k
Paul M. O’Byrne 29721 22141 6472 510 37.1k
Eugene R. Bleecker 19159 14246 4916 293 24.4k
Guy Brusselle 11692 11972 4182 389 21.9k
Dirkje S. Postma 16257 18310 3468 564 30.4k
Andrew J. Wardlaw 19199 12320 8190 252 26.6k
William W. Busse 25643 16406 8084 520 33.6k
Klaus F. Rabe 17533 24923 3438 500 36.2k

All Works

Loading papers...

Rankless by CCL
2026